Skip to main content


Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model

Fig. 5

Effect on Saos-2 subcutaneous xenograft tumor in nude mouse model following bi-weekly IV injection for 30 days of doxorubicin-conjugated BP NPs (1 µg doxorubicin per injection), free doxorubicin (1 µg per injection) and non-conjugated BP NPs (0.2 mg per injection). *T test p < 0.05 and error bars represent standard deviation

Back to article page